» Articles » PMID: 19948149

The Novel Neurotensin Analog NT69L Blocks Phencyclidine (PCP)-induced Increases in Locomotor Activity and PCP-induced Increases in Monoamine and Amino Acids Levels in the Medial Prefrontal Cortex

Overview
Journal Brain Res
Specialty Neurology
Date 2009 Dec 2
PMID 19948149
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Schizophrenia is a life-long, severe, and disabling brain disorder that requires chronic pharmacotherapy. Because current antipsychotic drugs do not provide optimal therapy, we have been developing novel treatments that focus on receptors for the neuropeptide neurotensin (NT). NT69L, an analog of neurotensin(8-13), acts like an atypical antipsychotic drug in several dopamine-based animal models used to study schizophrenia. Another current animal model utilizes non-competitive antagonists of the NMDA/glutamate receptor, such as the psychotomimetic phencyclidine (PCP). In the present study, we investigated the effects of NT69L on PCP-induced behavioral and biochemical changes in the rat. The top of an activity chamber was modified to allow us to perform microdialysis in rat brain, while simultaneously recording the locomotor activity of a rat. PCP injection significantly increased activity as well as the extracellular concentration of norepinephrine (NE), 5-HT, dopamine (DA), and glutamate in the medial prefrontal cortex (mPFC). Pretreating with NT69L blocked the PCP-induced hyperactivity as well as the increase of DA, 5-HT, NE, and glutamate in mPFC. Interestingly and unexpectedly, NT69L markedly increased glycine levels, while PCP was without effect on glycine levels. Thus, NT69L showed antipsychotic-like effects in this glutamate-based animal model for studying schizophrenia. Previous work from our group suggests that NT69L also has antipsychotic-like effects in dopaminergic and serotonergic rodent models. Taken together, these data suggest that NT69L in particular and NT receptor agonists in general, will be useful as broad-spectrum antipsychotic drugs.

Citing Articles

Dysfunction of the NMDA Receptor in the Pathophysiology of Schizophrenia and/or the Pathomechanisms of Treatment-Resistant Schizophrenia.

Okubo R, Okada M, Motomura E Biomolecules. 2024; 14(9).

PMID: 39334894 PMC: 11430065. DOI: 10.3390/biom14091128.


The 46.1 Antibody Mediates Neurotensin Uptake into the CNS and the Effects Depend on the Route of Intravenous Administration.

Georgieva J, Katt M, Ye Z, Umlauf B, Wenthur C, Shusta E Pharmaceutics. 2022; 14(8).

PMID: 36015332 PMC: 9414616. DOI: 10.3390/pharmaceutics14081706.


Candidate Strategies for Development of a Rapid-Acting Antidepressant Class That Does Not Result in Neuropsychiatric Adverse Effects: Prevention of Ketamine-Induced Neuropsychiatric Adverse Reactions.

Okada M, Kawano Y, Fukuyama K, Motomura E, Shiroyama T Int J Mol Sci. 2020; 21(21).

PMID: 33114753 PMC: 7662754. DOI: 10.3390/ijms21217951.


Oxytocin attenuates phencyclidine hyperactivity and increases social interaction and nucleus accumben dopamine release in rats.

Kohli S, King M, Williams S, Edwards A, Ballard T, Steward L Neuropsychopharmacology. 2018; 44(2):295-305.

PMID: 30120410 PMC: 6300530. DOI: 10.1038/s41386-018-0171-0.


Ethanol-induced alterations of amino acids measured by in vivo microdialysis in rats: a meta-analysis.

Fliegel S, Brand I, Spanagel R, Noori H In Silico Pharmacol. 2014; 1:7.

PMID: 25505652 PMC: 4230485. DOI: 10.1186/2193-9616-1-7.


References
1.
Berendse H, Galis-de Graaf Y, Groenewegen H . Topographical organization and relationship with ventral striatal compartments of prefrontal corticostriatal projections in the rat. J Comp Neurol. 1992; 316(3):314-47. DOI: 10.1002/cne.903160305. View

2.
Sanz B, Exposito I, Mora F . Effects of neurotensin on the release of glutamic acid in the prefrontal cortex and striatum of the rat. Neuroreport. 1993; 4(10):1194-6. View

3.
Boules M, Iversen I, Oliveros A, Shaw A, Williams K, Robinson J . The neurotensin receptor agonist NT69L suppresses sucrose-reinforced operant behavior in the rat. Brain Res. 2006; 1127(1):90-8. DOI: 10.1016/j.brainres.2006.10.025. View

4.
CLEGHORN J, Franco S, Szechtman B, Kaplan R, Szechtman H, Brown G . Toward a brain map of auditory hallucinations. Am J Psychiatry. 1992; 149(8):1062-9. DOI: 10.1176/ajp.149.8.1062. View

5.
Carraway R, Leeman S . The isolation of a new hypotensive peptide, neurotensin, from bovine hypothalami. J Biol Chem. 1973; 248(19):6854-61. View